<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Diphtheria, tetanus toxoids, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type B, hepatitis B conjugate vaccine (DTaP-IPV-Hib-HepB): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Diphtheria, tetanus toxoids, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type B, hepatitis B conjugate vaccine (DTaP-IPV-Hib-HepB): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Diphtheria, tetanus toxoids, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type B, hepatitis B conjugate vaccine (DTaP-IPV-Hib-HepB): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_pediatric" data-topicid="130101" href="/d/html/130101.html" rel="external">see "Diphtheria, tetanus toxoids, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type B, hepatitis B conjugate vaccine (DTaP-IPV-Hib-HepB): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F55197788"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Vaxelis</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F55212078"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Infanrix Hexa</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F11562071"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Vaccine;</li>
<li>
                        Vaccine, Inactivated (Bacterial);</li>
<li>
                        Vaccine, Inactivated (Viral)</li></ul></div>
<div class="block dop drugH1Div" id="F11562136"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="130101" href="/d/html/130101.html" rel="external">see "Diphtheria, tetanus toxoids, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type B, hepatitis B conjugate vaccine (DTaP-IPV-Hib-HepB): Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Consult CDC/ACIP annual immunization schedules for additional information including specific detailed recommendations for catch-up scenarios and/or care of patients with high-risk conditions. According to ACIP, doses administered ≤4 days before minimum interval or age are considered valid; however, local or state mandates may supersede this timeframe (ACIP [Kroger 2023]).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="937db9e2-a48f-4ad7-9c9f-6b65d8ae8b3e">Primary immunization</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Primary immunization:</b>
<b>Note:</b> Whenever feasible, the same manufacturer should be used for all doses of the vaccination series; however, vaccination should not be deferred if a specific brand is not known or is not available (ACIP [Kroger 2023]; NACI/CATMAT 2016). See manufacturer labeling for specific interchangeability details.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Vaxelis:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants ≥6 weeks and Children &lt;5 years: IM: 0.5 mL per dose for a total of 3 doses administered at 2, 4, and 6 months of age; the first dose may be administered as early as 6 weeks of age; minimum interval between doses is 4 weeks for the first 2 doses; the third dose should not be administered before 6 months of age. Preterm infants should be vaccinated according to their chronological age from birth (ACIP [Oliver 2020]; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Infanrix </i>
<i>hexa [Canadian product]: </i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Primary Immunization:</i>
<i>Canadian labeling:</i> Infants ≥6 weeks and Children &lt;2 years: IM: 0.5 mL per dose for 2 or 3 doses administered ≥1 month apart; infants ≥6 weeks of age born prior to 24 weeks gestation should receive 3 doses; refer to current provincial and territorial immunization recommendations (NACI/CATMAT 2020; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Booster Immunization: Canadian labeling:</i>
<i></i>Infants ≥11 months and Children &lt;5 years: IM: 0.5 mL per dose for a single dose; refer to current provincial and territorial immunization recommendations to determine need and timing for booster dose (NACI/CATMAT 2020; manufacturer's labeling).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="030231b8-f8a7-4a85-8830-e75f8b3f4505">Catch-up immunization</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Catch-up immunization</b>: Infants and Children &lt;5 years: IM: 0.5 mL per dose; refer to current immunization recommendations for specific schedule and timing of doses based on patient age and vaccine history.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51117842"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51117843"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F11562105"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">
<b>
<b>All serious adverse reactions must be reported to the US Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967 or online at </b>
<a href="/external-redirect?target_url=https%3A%2F%2Fvaers.hhs.gov%2Fesub%2Findex&amp;token=8m3rK0tzv73hmwLVujPJP0lWL2FxLWQizZTxo5kD83IMEaCGiDnUFaD%2B0my2cUJQ&amp;TOPIC_ID=16462" target="_blank">
<b>https://vaers.hhs.gov/esub/index</b></a>
<b>.</b></b></p>
<p style="text-indent:-2em;margin-left:2em;">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported within 5 days of vaccination at 2, 4, and 6 months of age in infants given Vaxeis concomitantly with Prevnar 13 vaccine and RotaTeq vaccine.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Decreased appetite (23% to 29%), vomiting (10% to 13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Erythema at injection site (26% to 32%), pain at injection site (45% to 53%), swelling at injection site (19% to 23%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Drowsiness (41% to 56%), irritability (55% to 62%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Crying (45% to 52%), fever (≥38°C: 19% to 29%; ≥39.5°C: ≤2%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema, facial edema, swelling of injected limb</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema multiforme, skin rash, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactic shock, anaphylaxis, angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Seizure</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Febrile seizure, hypotonic/hyporesponsive episode</p></div>
<div class="block coi drugH1Div" id="F11562075"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Severe allergic reaction to any component of vaccine or formulation; encephalopathy of unknown etiology within 1 week following prior vaccination with a pertussis-containing vaccine; progressive neurologic disorders, including infantile spasms, uncontrolled epilepsy, or progressive encephalopathy, until a treatment regimen is established and the condition is stabilized.</p>
<p style="text-indent:-2em;margin-left:2em;">Infanrix hexa [Canadian product]: Additional contraindications: Use in persons ≥7 years of age; moderate or severe acute febrile illness or acute infection.</p></div>
<div class="block war drugH1Div" id="F11562076"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Reactions from previous pertussis vaccination: Carefully consider use and weigh risks/benefits in patients with history of any of the following effects from previous administration of a pertussis-containing vaccine: Fever ≥40.5°C (105°F) within 48 hours of unknown cause; seizures with or without fever occurring within 3 days; persistent, inconsolable crying episodes lasting ≥3 hours and occurring within 48 hours; collapse or shock-like state (hypotonic-hyporesponsive episode) occurring within 48 hours. Vaccine should not be administered in patients with a history of severe allergic reaction after a previous dose or encephalopathy not attributable to another cause within 7 days following a previous dose of pertussis-containing vaccine (CDC/ACIP [Liang 2018]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Syncope: Syncope has been reported with use of injectable vaccines and may result in serious secondary injury (eg, skull fracture, cerebral hemorrhage); typically reported in adolescents and young adults and within 15 minutes after vaccination. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Acute illness: The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. Postpone administration in patients with moderate or severe acute illness (with or without fever); vaccination should not be delayed for patients with mild acute illness (with or without fever) (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Bleeding disorders: Use with caution in patients with a history of bleeding disorders (including thrombocytopenia); bleeding/hematoma may occur from IM administration; if the patient receives antihemophilia or other similar therapy, IM injection can be scheduled shortly after such therapy is administered (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Brachial neuritis: Has occurred following tetanus toxoid-containing vaccines; use with caution (CDC/ACIP [Liang 2018]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Guillain-Barré syndrome: Use with caution if Guillain-Barré syndrome occurred within 6 weeks of prior tetanus toxoid-containing vaccine (CDC/ACIP [Liang 2018]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Neurologic disorders: Use pertussis-containing vaccines with caution in patients with progressive neurologic disease including infantile spasms, uncontrolled seizure, or a progressive encephalopathy, or conditions predisposing to seizures; the Advisory Committee on Immunization Practices (ACIP) guidelines recommend deferring immunization until health status can be assessed and condition stabilized (CDC/ACIP [Liang 2018]). Per the manufacturer, it is contraindicated to administer vaccine until a treatment regimen is established and the condition is stabilized.</p>
<p style="text-indent:-2em;margin-left:4em;">• Poliomyelitis: Infanrix hexa [Canadian product]: Defer elective immunization of individuals ≥6 months of age during outbreaks of poliomyelitis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anticoagulant therapy: Use with caution in patients receiving anticoagulant therapy; bleeding/hematoma may occur from IM administration (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Vaccines: In order to maximize vaccination rates, the ACIP recommends simultaneous administration (ie, &gt;1 vaccine on the same day at different anatomic sites) of all age-appropriate vaccines (live or nonlive) for which a person is eligible at a single visit, unless contraindications exist. The use of combination vaccines is generally preferred over separate injections, taking into consideration provider assessment, patient preference, and adverse events. When using combination vaccines, the minimum age for administration is the oldest minimum age for any individual component; the minimum interval between dosing is the greatest minimum interval between any individual components. The ACIP prefers each dose of a specific vaccine in a series come from the same manufacturer when possible; however, vaccination should not be deferred because a specific brand name is unavailable (ACIP [Kroger 2023]). An increased incidence of febrile reactions, convulsions (with or without fever) and hypotonic hyporesponsive episode have been observed with concomitant use of Infanrix hexa [Canadian product] and pneumococcal conjugate vaccine.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Altered immunocompetence: Postpone vaccination during periods of severe immunosuppression (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy [including high-dose corticosteroids]) if appropriate; may have a reduced response to vaccination. May be used in patients with HIV infection. In general, household and close contacts of persons with altered immunocompetence may receive all age-appropriate vaccines. Non-live vaccines should be administered ≥2 weeks prior to planned immunosuppression when feasible; non-live vaccines administered during chemotherapy should be readministered after immune competence is regained (ACIP [Kroger 2023]; IDSA [Rubin 2014]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Apnea has been reported following IM vaccine administration in premature infants; consider clinical status implications. In general, preterm infants should be vaccinated at the same chronological age as full-term infants (AAP [Saari 2003]; ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Aluminum: Formulation may contain aluminum.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neomycin: Formulation contains trace amounts of neomycin; use caution in patients with prior hypersensitivity to neomycin.</p>
<p style="text-indent:-2em;margin-left:4em;">• Polymyxin B: Formulation contains trace amounts of polymyxin B; use caution in patients with prior hypersensitivity to polymyxin B.</p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Antipyretics: Antipyretics have not been shown to prevent febrile seizures. Antipyretics may be used to treat fever or discomfort following vaccination (ACIP [Kroger 2023]). One study reported that routine prophylactic administration of acetaminophen to prevent fever prior to vaccination decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula 2009).</p>
<p style="text-indent:-2em;margin-left:4em;">• Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval (ACIP [Kroger 2021]).</p></div>
<div class="block foc drugH1Div" id="F55197789"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Suspension, Intramuscular [preservative free]:</p>
<p style="text-indent:-2em;margin-left:4em;">Vaxelis: Diphtheria toxoid 15 Lf, tetanus toxoid 5 Lf, acellular pertussis antigens [pertussis toxin detoxified 20 mcg, filamentous hemagglutinin 20 mcg, pertactin 3 mcg, fimbriae (types 2 and 3) 5 mcg], inactivated polioviruses [type 1 (Mahoney) 29 D-antigen units (DU), type 2 (MEF-1) 7 DU, type 3 (Saukett) 26 DU], polyribosylribitol phosphate of H. influenzae type b 3 mcg [bound to Neisseria meningitidis OMPC 50 mcg], HBsAg 10 mcg per 0.5 ml (0.5 mL) [latex free; contains albumin bovine, formaldehyde solution, neomycin, polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;">Suspension Prefilled Syringe, Intramuscular [preservative free]:</p>
<p style="text-indent:-2em;margin-left:4em;">Vaxelis: Diphtheria toxoid 15 Lf, tetanus toxoid 5 Lf, acellular pertussis antigens [pertussis toxin detoxified 20 mcg, filamentous hemagglutinin 20 mcg, pertactin 3 mcg, fimbriae (types 2 and 3) 5 mcg], inactivated polioviruses [type 1 (Mahoney) 29 D-antigen units (DU), type 2 (MEF-1) 7 DU, type 3 (Saukett) 26 DU], polyribosylribitol phosphate of H. influenzae type b 3 mcg [bound to Neisseria meningitidis OMPC 50 mcg], HBsAg 10 mcg per 0.5 ml (0.5 mL) [latex free; contains albumin bovine, formaldehyde solution, neomycin, polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F55197787"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block dinfoc drugH1Div" id="F55212079"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Suspension, Intramuscular:</p>
<p style="text-indent:-2em;margin-left:4em;">Infanrix Hexa: Diphtheria toxoid 25 Lf, filamentous hemagglutinin 25 mcg, HBsAg 10 mcg, pertactin 8 mcg, pertussis toxoid 25 mcg, tetanus toxoid 10 Lf, type 1 poliovirus 40 D antigen units, type 2 poliovirus 8 D antigen units and type 3 poliovirus 32 D antigen units, <i>Haemophilus</i> b capsular polysaccharide 10 mcg [bound to tetanus toxoid ~25 mcg] per 0.5 mL (0.5 mL) [contains aluminum, neomycin sulfate (trace amounts), polymyxin B (trace amounts), polysorbate 20, and polysorbate 80; Pediarix vaccine used to reconstitute Hib forms Infanrix Hexa]</p></div>
<div class="block admp drugH1Div" id="F52614473"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: IM: Administer by IM injection only; in infants, preferably in the anterolateral aspects of the thigh; administer in deltoid muscle of the upper arm in older children (Infanrix hexa Canadian product monograph); do not inject in the gluteal area. If injecting in the deltoid muscle, use proper injection technique (eg, injecting in the central, thickest part of the muscle) to reduce the risk of shoulder injury related to vaccine administration (Cross 2016; Foster 2013). Do not mix with other vaccines or injections; separate needles and syringes should be used for each injection (ACIP [Kroger 2023]; NACI/CATMAT 2020).</p></div>
<div class="block use drugH1Div" id="F11562072"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and </b>
<i>
<b>Haemophilus influenzae</b>
<b>type</b></i>
<b> b disease prevention: </b></p>
<p style="text-indent:-2em;margin-left:4em;">Active immunization against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and <i>Haemophilus influenzae</i> type b in infants and children 6 weeks through 4 years of age.</p>
<p style="text-indent:-2em;margin-left:4em;">The Advisory Committee on Immunization Practices (ACIP) recommends Vaxelis for primary vaccination against DTaP, HepB, IPV, and Hib at ages 2, 4, and 6 months; use is not recommended for the subsequent doses, but doses do not need to be repeated if Vaxelis is inadvertently administered for these doses (CDC/ACIP [Oliver 2020]). Vaxelis may also be used in patients &lt;5 years of age as part of an appropriate catch-up schedule.</p></div>
<div class="block mst drugH1Div" id="F11562066"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Infanrix Hexa may be confused with Infanrix or Infanrix-Polio</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Infanrix Hexa is supplied in two vials, one containing DTaP-HepB-IPV liquid and one containing Hib powder, which must be mixed together in order to administer the recommended vaccine components. Errors have occurred when both vials have not been used or are mixed improperly, ensure proper preparation before administering.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299217"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F12608708"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetaminophen: May diminish the therapeutic effect of Vaccines. Management: Consider avoiding routine prophylactic use of acetaminophen before or during vaccine administration when possible. Acetaminophen is still recommended to treat fevers and/or pain that occurs after vaccination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anti-CD20 B-Cell Depleting Therapies: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Give inactivated vaccines at least 2 weeks prior to initiation or 6 months after anti-CD20 B-cell depleting therapies. If vaccinated prior to B cell recovery, consider assessing immune response to vaccination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Give inactivated vaccines at least 2 weeks prior to initiation of cladribine when possible. Patients vaccinated less than 14 days before initiating or during cladribine should be revaccinated at least 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Administer vaccines at least 2 weeks prior to immunosuppressive corticosteroids if possible. If patients are vaccinated less than 14 days prior to or during such therapy, repeat vaccination at least 3 months after therapy if immunocompetence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elivaldogene Autotemcel: May enhance the adverse/toxic effect of Vaccines. Specifically, there may be a greater risk for contracting an infection from any live vaccine. Elivaldogene Autotemcel may diminish the therapeutic effect of Vaccines. Management: Administration of vaccines is not recommended in the 6 weeks before myeloablative conditioning, and until hematologic recovery after elivaldogene autotemcel treatment.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting fingolimod. If vaccinated during fingolimod therapy, revaccinate 2 to 3 months after fingolimod discontinuation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Cytotoxic Chemotherapy): May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Give inactivated vaccines at least 2 weeks prior to initiation of chemotherapy when possible. Patients vaccinated less than 14 days before initiating or during chemotherapy should be revaccinated at least 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Miscellaneous Oncologic Agents): May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 3 after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Therapeutic Immunosuppressant Agents): May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 2 to 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Meningococcal (Groups A / C / Y and W-135) Conjugate Vaccine: Tetanus Toxoids Vaccines may diminish the therapeutic effect of Meningococcal (Groups A / C / Y and W-135) Conjugate Vaccine.  Management: When possible, administer the meningococcal polysaccharide (groups A / C / Y and W-135) conjugate vaccine (Nimenrix brand) either together with, or at least one month before, a tetanus toxoids-containing vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Administer vaccines at least 2 weeks prior to methotrexate initiation, if possible. If patients are vaccinated less than 14 days prior to or during methotrexate therapy, repeat vaccination at least 3 months after therapy if immunocompetence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propacetamol: May diminish the therapeutic effect of Vaccines. Management: Consider avoiding routine prophylactic use of propacetamol before or during vaccine administration when possible. Propacetamol is still recommended to treat fevers and/or pain that occurs after vaccination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Siponimod: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Avoid administration of vaccines (inactivated) during treatment with siponimod and for 1 month after discontinuation due to potential decreased vaccine efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teplizumab: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Vaccination with inactivated or non-replicating vaccines is not recommended in the 2 weeks prior to teplizumab therapy, during treatment, or for 6 weeks following completion of therapy.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F11562073"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">This combination vaccine is not indicated for use in patients of reproductive age.</p></div>
<div class="block brc drugH1Div" id="F11562074"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">This combination vaccine is not indicated for use in patients who are breastfeeding. Breastfeeding infants should be vaccinated according to the recommended schedules (ACIP [Kroger 2023]).</p></div>
<div class="block mop drugH1Div" id="F11562139"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Observe for hypersensitivity for 15 minutes following administration (ACIP [Kroger 20212023]).</p></div>
<div class="block pha drugH1Div" id="F11562132"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Promotes active immunity to diphtheria, tetanus, pertussis, hepatitis B, poliovirus (types 1, 2, and 3), and <i>Haemophilus influenzae</i> type B by inducing production of specific antibodies and antitoxins.</p></div>
<div class="block phk drugH1Div" id="F11562126"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Onset: Immune response observed to all components 1 month following the 3-dose series.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F23670090"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Hexavac | Hexaxim</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Hexavac | Hexyon | Infanrix hexa | Vaxelis</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Hexaxim | Infanrix hexa</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Hexyon | Infanrix hexa</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Hexaxim</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Hexacima | Infanrix hexa</span>;</li>
<li>
<span class="countryCode">(BO)</span> <span class="country">Bolivia, Plurinational State of</span><span class="countrySeparator">: </span><span class="drugName">Hexaxim</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Hexaxim | Infanrix hexa</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Vaxelis</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Hexaxim</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Hexaxim</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Hexaxim | Infanrix hexa</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Hexacima | Hexavac | Infanrix hexa</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Hexavac | Hexyon | Infanrix hexa | Vaxelis</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Hexaxim</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Hexavac | Hexaxim | Infanrix hexa</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Hexacima | Hexavac | Hexyon | Vaxelis</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Hexavac | Hexyon | Infanrix hexa | Vaxelis</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Hexavac | Hexyon | Infanrix hexa | Vaxelis</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Infanrix hexa | Vaxelis</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Hexavac | Hexyon | Infanrix hexa | Vaxelis</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Hexaxim | Infanrix hexa</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Hexacima | Infanrix hexa</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Hexavac</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Hexaxim | Infanrix hexa</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Vaxelis</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Hexaxim | Infanrix hexa</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Hexavac | Hexyon | Infanrix hexa | Vaxelis</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Hexaxim</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Hexaxim</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Hexaxim</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Infanrix hexa</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Hexaxim</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Hexavac</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Hexyon</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Hexacima | Hexavac | Infanrix hexa | Vaxelis</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Hexaxim</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Hexacima | Hexaxim</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Hexaxim</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Infanrix hexa | Vaxelis</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Hexaxim | Hexyon | Infanrix hexa</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Hexaxim | Infanrix hexa</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Hexavac | Hexaxim | Infanrix hexa</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Hexaxim</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Hexacima | Hexaxim | Infanrix hexa</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Hexyon | Infanrix hexa</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Hexaxim</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Infanrix hexa</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Hexacima | Infanrix hexa | Vaxelis</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Infanrix hexa</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Hexaxim | Infanrix hexa</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Hexyon</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Hexaxim | Infanrix hexa</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Hexacima | Hexavac</span>;</li>
<li>
<span class="countryCode">(SV)</span> <span class="country">El Salvador</span><span class="countrySeparator">: </span><span class="drugName">Hexaxim</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Hexavac | Hexaxim</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Hexaxim | Infanrix hexa</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Hexaxim</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Hexaxim | Infanrix hexa</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Hexaxim | Infanrix hexa</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Hexaxim</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Hexaxim | Infanrix hexa</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Hexaxim | Infanrix hexa</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Hexaxim</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-acellular-pertussis-inactivated-poliovirus-haemophilus-influenzae-type-b-hepatitis-b-conjugate-vaccine-dtap-ipv-hib-hepb-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-acellular-pertussis-inactivated-poliovirus-haemophilus-influenzae-type-b-hepatitis-b-conjugate-vaccine-dtap-ipv-hib-hepb-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27166466">
<a name="27166466"></a>Cross GB, Moghaddas J, Buttery J, Ayoub S, Korman TM. Don't aim too high: avoiding shoulder injury related to vaccine administration. <i>Aust Fam Physician</i>. 2016;45(5):303-306.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-acellular-pertussis-inactivated-poliovirus-haemophilus-influenzae-type-b-hepatitis-b-conjugate-vaccine-dtap-ipv-hib-hepb-drug-information/abstract-text/27166466/pubmed" id="27166466" target="_blank">27166466</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23636163">
<a name="23636163"></a>Foster SL, Davis MV. Vaccine administration: preventing serious shoulder injuries. <i>J Am Pharm Assoc (2003)</i>. 2013;53(1):102-103. doi:10.1331/JAPhA.2013.13503<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-acellular-pertussis-inactivated-poliovirus-haemophilus-influenzae-type-b-hepatitis-b-conjugate-vaccine-dtap-ipv-hib-hepb-drug-information/abstract-text/23636163/pubmed" id="23636163" target="_blank">23636163</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Infanrix-hexa.1">
<a name="Infanrix-hexa.1"></a>Infanrix hexa (combined diphtheria and tetanus toxoids, acellular pertussis, hepatitis B [recombinant], inactivated poliomyelitis and adsorbed conjugated <i>Haemophilus influenzae</i> type b vaccine) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline Inc; September 2022.</div>
</li>
<li>
<div class="reference">
                  Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ACIP.1">
<a name="ACIP.1"></a>Kroger A, Bahta L, Long S, Sanchez P. General best practice guidelines for immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). <a href="https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf" target="_blank">https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf</a>. Updated 2023. Accessed April 20, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29702631">
<a name="29702631"></a>Liang JL, Tiwari T, Moro P, et al. Prevention of pertussis, tetanus, and diphtheria with vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR Recomm Rep</i>. 2018;67(2):1-44.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-acellular-pertussis-inactivated-poliovirus-haemophilus-influenzae-type-b-hepatitis-b-conjugate-vaccine-dtap-ipv-hib-hepb-drug-information/abstract-text/29702631/pubmed" id="29702631" target="_blank">29702631</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-acellular-pertussis-inactivated-poliovirus-haemophilus-influenzae-type-b-hepatitis-b-conjugate-vaccine-dtap-ipv-hib-hepb-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  National Advisory Committee on Immunization (NACI), Committee to Advise on Tropical Medicine and Travel (CATMAT). Canadian Immunization Guide. <a href="https://www.canada.ca/en/public-health/services/canadian-immunization-guide.html" target="_blank">https://www.canada.ca/en/public-health/services/canadian-immunization-guide.html</a>. Updated May 2020. Accessed November 11, 2020.</div>
</li>
<li>
<div class="reference">
                  National Advisory Committee on Immunization (NACI), Committee to Advise on Tropical Medicine and Travel (CATMAT). Principles of vaccine interchangeability: Canadian Immunization Guide.<a href="https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-1-key-immunization-information/page-7-principles-vaccine-interchangeability.html" target="_blank">https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-1-key-immunization-information/page-7-principles-vaccine-interchangeability.html</a>. Updated February 2016. Accessed November 11, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32027629">
<a name="32027629"></a>Oliver SE, Moore KL. Licensure of a diphtheria and tetanus toxoids and acellular pertussis, inactivated poliovirus, haemophilus influenzae type b conjugate, and hepatitis B vaccine, and guidance for use in infants. <i>MMWR Morb Mortal Wkly Rep</i>. 2020;69(5):136-139.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-acellular-pertussis-inactivated-poliovirus-haemophilus-influenzae-type-b-hepatitis-b-conjugate-vaccine-dtap-ipv-hib-hepb-drug-information/abstract-text/32027629/pubmed" id="32027629" target="_blank">32027629</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19837254">
<a name="19837254"></a>Prymula R, Siegrist CA, Chlibek R, et al, “Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,” <i>Lancet</i>, 2009, 374(9698):1339-50.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-acellular-pertussis-inactivated-poliovirus-haemophilus-influenzae-type-b-hepatitis-b-conjugate-vaccine-dtap-ipv-hib-hepb-drug-information/abstract-text/19837254/pubmed" id="19837254" target="_blank">19837254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24311479">
<a name="24311479"></a>Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. <i>Clin Infect Dis</i>. 2014;58(3):e44-e100.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-acellular-pertussis-inactivated-poliovirus-haemophilus-influenzae-type-b-hepatitis-b-conjugate-vaccine-dtap-ipv-hib-hepb-drug-information/abstract-text/24311479/pubmed" id="24311479" target="_blank">24311479</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12837889">
<a name="12837889"></a>Saari TN; American Academy of Pediatrics Committee on Infectious Diseases. Immunization of preterm and low birth weight infants. American Academy of Pediatrics Committee on Infectious Diseases. <i>Pediatrics</i>. 2003;112(1 Pt 1):193-198.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-acellular-pertussis-inactivated-poliovirus-haemophilus-influenzae-type-b-hepatitis-b-conjugate-vaccine-dtap-ipv-hib-hepb-drug-information/abstract-text/12837889/pubmed" id="12837889" target="_blank">12837889</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-acellular-pertussis-inactivated-poliovirus-haemophilus-influenzae-type-b-hepatitis-b-conjugate-vaccine-dtap-ipv-hib-hepb-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vaxelis.1">
<a name="Vaxelis.1"></a>Vaxelis (diphtheria and tetanus toxoids and acellular pertussis, inactivated poliovirus, <i>Haemophilus </i>b conjugate and hepatitis B vaccine) [prescribing information]. Swiftwater, PA: MSP Vaccine Co; October 2022.</div>
</li>
<li>
<div class="reference">
                  World Health Organization (WHO). Guiding principles for immunization activities during the COVID-19 pandemic: interim guidance, 26 March 2020. Published March 26, 2020. Available at https://apps.who.int/iris/handle/10665/331590
                  </div>
</li></ol></div><div id="topicVersionRevision">Topic 16462 Version 146.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
